

学位論文抄録

Abstract of Thesis

Endometrial cancer with a *POLE* mutation progresses frequently through the type I pathway despite its high-grade endometrioid morphology:

A cohort study at a single institution in Japan

(日本人における *POLE* 変異子宮内膜癌の臨床病理学的解析: 単施設におけるコホート研究)

モンスール・マヒナ

Mahina Monsur

Department of Obstetrics and Gynecology, Medical Sciences Major,
Doctoral Course of the Graduate School of Medical Sciences,
Kumamoto University

Academic advisor

Professor Katabuchi Hidetaka

Department of Obstetrics and Gynecology, Medical Sciences Major,
Doctoral Course of the Graduate School of Medical Sciences,
Kumamoto University

Abstract of the Thesis

Background and Purpose:

Endometrial cancer (EC) with a *POLE* mutation is frequently correlated with high-grade endometrioid histology, which represents immunohistochemical and genetic heterogeneity in the dualistic classification of EC, type I and type II. The present study aimed to assess the clinicopathology and pathogenesis of *POLE*-mutated EC due to the scarcity of related information for Asian women.

Methods:

Exonuclease domain variants spanning exons 9 to 14 in the *POLE* gene were examined in tissues of Japanese women with EC by Sanger sequencing. The tumor mutation burden (TMB) in the tissues was assessed when a *POLE* variant of unknown significance was identified. In the *POLE*-mutated EC tissues, the immunostaining expression of CD8, estrogen receptor (ER), progesterone receptor (PR), and p53 was evaluated, and the *POLE* variants in cancer and atypical endometrial hyperplasia (AEH) lesions were assessed by laser-capture microdissection.

Results:

POLE variants were identified in five patients (3.9%) with high-grade endometrioid carcinoma among 127 eligible patients with EC: S459F was found in two and P441P, which was of unknown significance, was found in three tissues with a high TMB. The five cancer tissues showed marked CD8-positive cell infiltration and coexisted with normal endometrium and/or AEH. In the four patients with AEH, both AEH and cancer cells showed ER and PR positivity and harbored the same *POLE* mutation. In two patients with cancer lesions that showed a subclonal overexpression pattern of p53, the same subclonal pattern was observed in AEH.

Conclusions:

EC with a *POLE* mutation progresses through the type I pathway, even though it frequently shows high-grade endometrioid morphology. The common *POLE* mutation sites in EC might vary among races.